Introducing Melanoma Institute Australia's Conjoint Medical Directors
14 March 2017
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Professor Long is a world-renowned clinical medical oncologist and melanoma researcher who is also President Elect for the prestigious international Society for Melanoma Research. She leads an extensive clinical trials team and research laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma.
Professor Scolyer is a world- leading surgical pathologist and melanoma researcher who has authored more than 450 seminal publications on this disease. Professor Scolyer’s expertise has already delivered exponential improvements in diagnosis and the staging of melanoma which determines a patient’s treatment pathway.
Together with their colleagues at MIA, they are changing the face of melanoma diagnosis and treatment in Australia and around the world.
‘Quite simply, I want to make a difference,” Professor Long said. ‘’I’d love to eradicate melanoma and put ourselves out of a job. That is the ultimate goal.”
‘Even if we haven’t eradicated melanoma in the next five years, I’d like to think we can control it long term so people don’t die of this disease,” Professor Scolyer added.
Sharing the Medical Director role means double the expertise and double the perspective on challenges. Both Professors believe their partnership will be crucial to leading Melanoma Institute Australia towards breaking new ground in melanoma diagnosis and treatment.
‘We know that ultimately prevention is better than cure, so we have to attack the disease at different levels from education, prevention, screening, early diagnosis, and by providing the best early treatment for the best outcomes,’ Professor Scolyer said.
‘The key to tackling melanoma is definitely collaboration, communication and sharing knowledge,” Professor Long added.
Melanoma Institute Australia is the leading centre in the world with a single focus on melanoma care, research and education.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.